Get the Stockscreener App
0.53
6.80%
-0.0387
After Hours:
.52
-0.01
-1.89%
Can-Fite Biopharma Ltd ADR stock is traded at $0.53, with a volume of 314.01K.
It is down -6.80% in the last 24 hours and down -19.16% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$0.5687
Open:
$0.57
24h Volume:
314.01K
Relative Volume:
1.45
Market Cap:
$816.94K
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.1767
EPS:
-3
Net Cash Flow:
-
1W Performance:
-14.52%
1M Performance:
-19.16%
6M Performance:
-62.09%
1Y Performance:
-76.44%
1-Day Range:
$0.5101
$0.5799
1-Week Range:
$0.5101
$0.6365
52-Week Range:
$0.5101
$3.12
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.53 | 9.71M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Why Can Fite Biopharma Ltd Sponsored ADR stock could outperform next yearGlobal Markets & Weekly Return Optimization Alerts - newser.com
Will Can Fite Biopharma Ltd Sponsored ADR stock beat growth indexesMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Why pension funds invest in Can Fite Biopharma Ltd Sponsored ADR stockJuly 2025 Selloffs & Reliable Trade Execution Plans - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock fits value portfolios2025 Bull vs Bear & Smart Allocation Stock Reports - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock expanding market penetration2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Is Can Fite Biopharma Ltd Sponsored ADR stock a contrarian opportunityEarnings Miss & Real-Time Volume Triggers - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong buy callEarnings Beat & High Accuracy Swing Entry Alerts - newser.com
Analyzing recovery setups for Can Fite BioPharma Ltd. Depositary Receipt investorsJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Institutional scanner results for Can Fite BioPharma Ltd. Depositary ReceiptMarket Performance Recap & Smart Money Movement Alerts - newser.com
Developing predictive dashboards with CISS dataTreasury Yields & Technical Analysis for Trade Confirmation - newser.com
Is a relief rally coming for Inovio Pharmaceuticals Inc. holders2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com
Smart tools for monitoring Can Fite BioPharma Ltd. Depositary Receipt’s price action2025 Market Overview & Precise Buy Zone Tips - newser.com
Order flow analysis tools used on BOOMWatch List & Accurate Technical Buy Alerts - newser.com
Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital - Defense World
Can swing trading help recover from Crane NXT Co. lossesMarket Growth Summary & AI Optimized Trade Strategies - Newser
Has FVRR formed a bullish divergence2025 Key Lessons & Low Risk High Win Rate Picks - Newser
Applying sector rotation models to Vale S.A. Depositary ReceiptJuly 2025 Catalysts & Reliable Price Action Trade Plans - Newser
Sentiment analysis tools applied to Vertical Aerospace Ltd.2025 Dividend Review & Weekly Setup with ROI Potential - Newser
Using RSI to spot recovery in ALDFUJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - Newser
Fragrances Inc.Earnings Growth Report & Stepwise Swing Trade Plans - Newser
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):